Home Blood Test for Alzheimer's Disease Measurement
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
- Age
- 40 – 90
- Sex
- Any
- Study type
- Observational
- Participants needed
- 1,000 (estimated)
- Sponsor
- Neurogen Biomarking LLC · Industry
This trial is looking for people who either have Alzheimer's disease or don’t have it but have cognitive impairment. Participants will help compare blood samples collected at home to those taken in a clinic to measure a certain biomarker linked to Alzheimer's.
You may be able to join if
- I am between 40 and 90 years old
- I have been diagnosed with Alzheimer's using PET/CSF
- I have no amyloid presence and have cognitive issues
- I can do the blood collection at home and in the clinic
- I can get help from a caregiver if needed
You may not be able to join if
- I have uncontrolled health issues
- I have had recent surgery or a hospital stay in the past 3 months
- I have participated in another dementia drug trial in the past 2 months
- I am pregnant
- I have previously used Donanemab or Lecanemab
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThis study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.
Loading trial locations…